Algorae Says TGA Reviews Have Risen To Seven As First Customer Receipts Begin
1AI: $0.009 +0.00% · MC: $18M
At its AGM, Algorae Pharmaceuticals said seven product registrations are now under TGA review, up from five reported in its September-quarter update, and first customer receipts arrived during that quarter. The company also said its portfolio now exceeds 20 products and that first supply under its NSW Health arrangement is expected this quarter; shareholders passed all resolutions listed in the meeting results.

Comments